Gene · 10457
Papers2,043
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,043
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy. | Cell | 2026 | 42349383 | PubTator, text mining | PubMed |
| CAR T targets: AI takes the wheel. | Cell | 2026 | 42349381 | PubTator, text mining | PubMed |
A report of thirteen non-conventional FLCN-mutated (renal) tumors (FMT) and a discussion of proposed diagnostic criteria, convergent FLCN/TFEB and FLCN/MITF E318K signaling, and FLCN immunohistochemistry. | Hum Pathol | 2026 | 42315013 | PubTator, text mining | PubMed |
| Genetic architecture of 67 oral diseases and their links to systemic diseases. | HGG Adv | 2026 | 42310951 | PubTator, text mining | PubMed |
| TYRP1 defines a proliferative melanoma cell subpopulation, driving malignant progression and therapy resistance via the GPNMB-Notch1-SOX10/MITF axis. | J Transl Med | 2026 | 42310652 | PubTator, text mining | PubMed |
| Parotid Oncocytomas Express the Glycoprotein Non-metastatic Melanoma Protein B (GPNMB): A Potential Link with Birt-Hogg-Dubé Syndrome. | Head Neck Pathol | 2026 | 42295526 | PubTator, text mining | PubMed |
| CD14+CD16+ monocyte-derived TREM2 macrophages promote lung fibrosis in systemic sclerosis-interstitial lung disease. | Front Immunol | 2026 | 42292441 | PubTator, text mining | PubMed |
| From Lysosomal Storage to Neurodegeneration: Sphingolipid Signaling as a Driver of CNS Pathology and Biomarker Strategy in Neuronopathic Gaucher Disease. | Int J Mol Sci | 2026 | 42278317 | PubTator, text mining | PubMed |
| Circulating cell type senescence signatures track distinct dimensions of health status and trajectories in human longitudinal cohorts. | Cell Rep | 2026 | 42276069 | PubTator, text mining | PubMed |
| GPNMB immunohistochemistry distinguishes diagnostically challenging cases of lymphangioleiomyomatosis from other mesenchymal neoplasms presenting with cystic lung metastases. | Hum Pathol | 2026 | 42269880 | PubTator, text mining | PubMed |
| GPNMB-ECD drives acquired resistance to osimertinib in NSCLC via inducing tumor cell cytoskeletal reorganization. | Cell Mol Biol Lett | 2026 | 42260371 | PubTator, text mining | PubMed |
| Multi-omic profiling identifies TREM2+ lipid-laden macrophages as inflammatory drivers and therapeutic targets of colorectal cancer liver metastasis. | Cancer Lett | 2026 | 42250756 | PubTator, text mining | PubMed |
| Selective vulnerability of dopaminergic neurons in Parkinson's disease connects PRKN and differential expression of CHCHD2 and GPNMB. | Cell Death Dis | 2026 | 42248828 | PubTator, text mining | PubMed |
| Papillary-Predominant FLCN-Mutated Renal Epithelial Neoplasm in Birt-Hogg-Dubé Syndrome. | Int J Surg Pathol | 2026 | 42231833 | PubTator, text mining | PubMed |
| ACTIN::MITF-rearranged tumor: a distinctive entity or a cutaneous PEComa with MITF alterations? A clinicopathological and molecular study of additional 5 cases. | Virchows Arch | 2026 | 42171769 | PubTator, text mining | PubMed |
| Foamy microglia link oxylipins to disease progression in multiple sclerosis. | Nat Neurosci | 2026 | 42168651 | PubTator, text mining | PubMed |
| Clinicopathologic characterization of renal tumors with Folliculin (FLCN) biallelic inactivation. | Virchows Arch | 2026 | 42166008 | PubTator, text mining | PubMed |
| Association of genomic driver mutation, histologic subtype, and mTORC1 biomarker expression in mTOR pathway-altered renal tumors. | Hum Pathol | 2026 | 42155824 | PubTator, text mining | PubMed |
| Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis. | Nat Genet | 2026 | 42151416 | PubTator, text mining | PubMed |
| Macrophage-related Genes were Discovered by Applying Highdimensional Weighted Gene Co-expression Network Analysis as Biomarkers for Esophageal Squamous Cell Carcinoma. | Curr Gene Ther | 2026 | 42136238 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10457/papers?page=3